Ashmore Group PLC (LON:ASHM) Investors: Shore Capital Reaffirms Hold Rating; Blue Martini Software (BLUE) Has 1.79 Sentiment

bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. The company has market cap of $10.04 billion. The Company’s product candidates include Lenti-D that is in phase II/III clinical studies for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in four clinical studies for the treatment of transfusion-dependent beta-thalassemia, and severe sickle cell disease. It currently has negative earnings. The companyÂ’s lead product candidate is bb2121, a chimeric antigen receptor T cell product candidate that is in Phase I trial for the treatment of relapsed/refractory multiple myeloma. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology; Kite Pharma, Inc. to develop and commercialize second generation T cell receptor product candidates against an antigen related to certain cancers associated with the human papilloma virus; and Medigene AG for the research and development of TCR product candidates directed against approximately four antigens for the treatment of cancer indications.

Shore Capital reiterated their Hold rating on shares of Ashmore Group PLC (LON:ASHM) in a research note issued on Thursday morning.

Analysts await bluebird bio, Inc. (NASDAQ:BLUE) to report earnings on February, 28. They expect $-1.63 EPS, up 13.30% or $0.25 from last year’s $-1.88 per share. After $-1.73 actual EPS reported by bluebird bio, Inc. for the previous quarter, Wall Street now forecasts -5.78% EPS growth.

Cormorant Asset Management Llc holds 3.33% of its portfolio in bluebird bio, Inc. for 137,500 shares. Eventide Asset Management Llc owns 412,000 shares or 3.21% of their US portfolio. Moreover, First Light Asset Management Llc has 1.57% invested in the company for 36,085 shares. The Pennsylvania-based Emerald Advisers Inc Pa has invested 1.03% in the stock. Baillie Gifford & Co, a United Kingdom-based fund reported 5.32 million shares.

The stock increased 2.65% or $5.25 during the last trading session, reaching $203.15. About 1.34M shares traded or 40.16% up from the average. bluebird bio, Inc. (BLUE) has risen 112.34% since February 8, 2017 and is uptrending. It has outperformed by 95.64% the S&P500.

Ratings analysis reveals 50% of Bluebirdbio’s analysts are positive. Out of 4 Wall Street analysts rating Bluebirdbio, 2 give it “Buy”, 1 “Sell” rating, while 1 recommend “Hold”. The lowest target is $80.0 while the high is $87.0. The stock’s average target of $83.50 is -58.90% below today’s ($203.15) share price. BLUE was included in 4 notes of analysts from October 14, 2016. The company was downgraded on Monday, February 6 by Roth Capital. The company was maintained on Thursday, December 1 by Maxim Group. The firm earned “Sell” rating on Friday, October 14 by Cantor Fitzgerald. The rating was maintained by Leerink Swann on Friday, October 14 with “Outperform”.

Among 20 analysts covering Ashmore Group PLC (LON:ASHM), 5 have Buy rating, 5 Sell and 10 Hold. Therefore 25% are positive. Ashmore Group PLC has GBX 450 highest and GBX 181 lowest target. GBX 359.05’s average target is -15.52% below currents GBX 425 stock price. Ashmore Group PLC had 209 analyst reports since July 29, 2015 according to SRatingsIntel. Goldman Sachs maintained the shares of ASHM in report on Tuesday, May 30 with “Buy” rating. The rating was maintained by Liberum Capital with “Hold” on Tuesday, September 8. The firm earned “Hold” rating on Thursday, February 9 by Peel Hunt. Societe Generale maintained the stock with “Buy” rating in Thursday, October 15 report. The firm earned “Buy” rating on Tuesday, December 13 by Goldman Sachs. The firm has “Neutral” rating by BNP Paribas given on Tuesday, September 29. Liberum Capital maintained Ashmore Group PLC (LON:ASHM) rating on Friday, January 26. Liberum Capital has “Hold” rating and GBX 367 target. Numis Securities maintained the shares of ASHM in report on Thursday, September 7 with “Hold” rating. On Thursday, October 19 the stock rating was maintained by Berenberg with “Buy”. The firm has “Hold” rating by Numis Securities given on Wednesday, November 23.